. 2021 May 14;6:100131. doi: 10.1016/j.resplu.2021.100131

Table 1.

Eligibility criteria.

Eligibility Criteria (individuals were eligible for the trial if they were a patient or visitor at a study recruitment site, > = 16 years of age, and met any one or more of the criteria below):	N = 30 No (%)
1 Has a history of taking opioids at recognized ‘high doses’ whether by prescription or otherwise, defined as >100 mg morphine equivalent per day.	10 (33.3)
2 Has required emergency care for opioid overdose previously.	11 (36.7)
3 Is enrolled in an opioid agonist treatment program or has been in the last 6 months, including methadone or buprenorphine maintenance.	12 (40)
4 Is being released from prison or has been released in the last 7 days, and has a history of non-medical opioid use.	0 (0)
5 Is receiving prescription opioid therapy with risk factors for adverse effects, including relevant comorbidities, co-prescriptions of benzodiazepines or other sedatives, concomitant ongoing alcohol use, or high-dose prescription opioid therapy.	16 (53.3)
6 Uses non-medical opioids, injects opioids, or acquires opioids from sources other than a pharmacy or health care setting.	15 (50.0)
7 Lives with or is in frequent contact with others who use opioids and would be eligible for the study.	14 (46.7)